

## H1 FY2021 Financial Results

Six-month period ended June 30, 2021

August 12, 2021 | Sosei Group Corporation (TSE:4565)

### Disclaimer

The material that follows is a presentation of general background information about Sosei Group Corporation and its subsidiaries (collectively, the "Company") as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities and should not be treated as giving investment advice to recipients. It is not targeted to the specific investment objectives, financial situation or particular needs of any recipient. It is not intended to provide the basis for any third-party evaluation of any securities or any offering of them and should not be considered as a recommendation that any recipient should subscribe for or purchase any securities.

The information contained herein is in summary form and does not purport to be complete. Certain information has been obtained from public sources. No representation or warranty, either express or implied, by the Company is made as to the accuracy, fairness, or completeness of the information presented herein and no reliance should be placed on the accuracy, fairness, or completeness of such information. The Company takes no responsibility or liability to update the contents of this presentation in the light of new information and/or future events. In addition, the Company may alter, modify or otherwise change in any manner the contents of this presentation, in its own discretion without the obligation to notify any person of such revision or changes.

This presentation contains "forward-looking statements," as that term is defined in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. The words "believe", "expect", "anticipate", "intend", "plan", "seeks", "estimates", "will" and "may" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements such or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those regarding our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, change and the Financial Services Agency of Japan. Although the Company believes that the expectations and assumptions reflected in the forward-looking statements are based on our prove to be accurate. The forward-looking statements with affiliate of this presentation and the company believes that the expectations and assumptions regarding our products obsolete, and other factors. These factors with affiliated entities, change and developments in technology which may render our products

This presentation does not constitute an offer, or invitation, or solicitation of an offer, to subscribe for or purchase any securities. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Recipients of this presentation are not to construe the contents of this summary as legal, tax or investment advice and recipients should consult their own advisors in this regard.

This presentation and its contents are proprietary confidential information and may not be reproduced, published or otherwise disseminated in whole or in part without the Company's prior written consent. These materials are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.

This presentation contains non-GAAP financial measures. The non-GAAP financial measures contained in this presentation are not measures of financial performance calculated in accordance with IFRS and should not be considered as replacements or alternatives to cash flow provided by operating activities or as a measure of liquidity (in each case, as determined in accordance with IFRS). Non-GAAP financial measures should be viewed in addition to, and not as a substitute for, analysis of the Company's results reported in accordance with IFRS.

References to "FY" in this presentation for periods prior to January 1, 2018 are to the 12-month periods commencing in each case on April 1 of the year indicated and ending on March 31 of the following year, and the ninemonth period from April 1, 2017 to December 31, 2017. From January 1, 2018 the Company changed its fiscal year to the 12-month period commencing in each case on January 1. References to "FY" in this presentation should be construed accordingly.

© Sosei Group Corporation. Sosei Heptares is the corporate brand and trademark of Sosei Group Corporation. Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.





Note: This material was created to explain the details of our company and is not intended to be used for investment decisions. In addition, the contents reflect the views of our company at the time of the creation of the material, and the accuracy of the information is not guaranteed. Investments should be made based on the independent views of investors





## Continued to execute on objectives and targeted investments

Summary Financial Highlights for the 6 months ended 30 June 2021



**Revenue of ¥3,123m** (\$28.9m) vs. ¥2,516m (\$23.2m) in H1 2020, driven by achievement of several progress-related milestone events and larger releases of deferred revenue from existing partners



**Cash Earnings Loss of ¥800m** (\$7.4m) vs. loss of ¥181m (\$1.7m) in H1 2020, as a result of planned increase in R&D investment (e.g., Muscarinic and prioritized in-house programs) and professional advisory fees



**Operating Loss of ¥1,849m** (\$17.1m) vs. loss of ¥1,136m (\$10.5m) in H1 2020 as a result of Oravi impairment and higher SBC<sup>1</sup> costs. Financing costs in the period largely offset by  $CC^2$  and  $FX^3$  gains



**Robust cash balance of ¥40.6bn,** an increase of ¥621m since the beginning of the year as a result of our balanced approach to investment and diversified partner base




**~¥10bn new growth capital raised after the period ended,** adding to our existing ~¥20.9bn funds earmarked to accelerate our strategic growth initiatives and investments

Our unique and balanced business model continues to support a sustainable financial profile

Notes: USD:JPY FX rates used - 2020 YTD average Rate: 108.25, 2021 YTD average rate; 108.11, 31 Dec 2020 spot rate: 103.52, 30 Jun 2021 spot rate: 110.54 1. SBC = Stock-Based Compensation 2. CC = Contingent Consideration 3. FX = Foreign Exchange



# Encouraging revenue growth offset by planned increase in R&D (muscarinic and priority in-house programs) and non-cash costs



- Revenue +24% vs. H1 2020 due to progress milestones from existing partners:
  - Pfizer (MC4 Ph 1 start)
  - Biohaven (CGRP Ph 1 start)
  - Genentech (Delivery of StaRs<sup>®</sup>)
  - Deferred revenue releases on AbbVie and Genentech collaborations
- Royalties from Novartis were stable

- Increased R&D investment in muscarinic M<sub>4</sub>R (HTL '878) and other prioritized high value creation in-house programs
- Strong interest from global partners for muscarinic programs
- H1 2020 spend lower than normal due to onset of pandemic in Mar-20, plus a large non-recurring supplier credit

- Oravi impaired in the period new distribution deal executed post period end expected to improve sales
- Higher SBC<sup>1</sup> costs from continued roll out of RSU<sup>2</sup> plans – aligning with shareholders
- Financing costs up from CB<sup>3</sup> issued in July 2020. H1 2020 result included realized RMF1<sup>4</sup> gain

SOSEI HEPTARES


Notes: <sup>1</sup> Non-IFRS measure; <sup>2</sup> Cash Operating Expenses = Cash R&D + Cash G&A

<sup>1.</sup> SBC = Stock-Based Compensation 2. RSU = Restricted Stock Units 3. CB = Convertible Bond 4. RMF1 = Regenerative Medicine Fund 1

# Encouraging revenue growth offset by planned increase in R&D (muscarinic and priority in-house programs) and non-cash costs (cont'd)

	JPY mi	illion	USD r	nillion
	6m ended 30 Jun 2020	6m ended 30 Jun 2021	6m ended 30 Jun 2020	6m ended 30 Jun 2021
Revenue	2,516	3,123	23.2	28.9
Cash Cost of Sales	(304)	(366)	(2.8)	(3.4)
Cash R&D	(1,500)	(2,382)	(13.9)	(22.0)
Cash G&A	(925)	(1,256)	(8.5)	(11.6)
Other Cash Income	32	81	0.3	0.7
Cash Earnings Loss	(181)	(800)	(1.7)	(7.4)
Non-Cash Costs	(955)	(1,049)	(8.8)	(9.7)
Operating Loss	(1,136)	(1,849)	(10.5)	(17.1)
Net Finance Costs	46	(32)	0.4	(0.3)
Equity Accounted Investments	(180)	488	(1.6)	4.5
Net Profit before income tax	(1,270)	(1,393)	(11.7)	(12.9)
Net Profit	(2,117)	(2,297)	(19.6)	(21.2)

Notes: USD:JPY FX rates used – 2020 YTD average rate: 108.25, 2021 YTD average rate: 108.11





## Sustainability of business model and corporate strategy is reflected in our robust and well capitalized balance sheet


2

	JPY million		USD	million	
	As of 31 Dec 2020	As of 30 Jun 2021	As of 31 Dec 2020	As of 30 Jun 2021	
Goodwill & intangibles	25,936	27,412	250.5	248.0	
Property, plant & equip.	3,824	3,915	36.9	35.4	
Cash at hand	40,008	1 40,629	386.5	1 367.5	
Equity Acc. investments	3,087	3,666	29.8	33.2	
Other financial assets	1,593	2 3,519	15.4	2 31.8	
Other assets	2,017	2,207	19.5	20.0	
Total Assets	76,465	81,348	738.6	735.9	
Convertible Bonds	14,789	14,918	142.9	135.0	
Other liabilities	9,295	10,674	89.7	96.5	
Total Liabilities	24,084	25,592	232.6	231.5	
Net Assets	52,381	55,756	506.0	504.4	

#### Commentary

- Small cash inflow when balances are aggregated in JPY, however weaker JPY in H1 2021 drove a reduction in total cash balance when aggregated in USD
  - Increase due to positive revaluation of several investment securities, including significant increase in value of our new Centessa Pharma holding following its IPO

#### Cash Flow Bridge (6m ended 30 Jun 2021)



SOSEI HEPTARES

Notes: USD:JPY FX rates used – 31 Dec 2020 spot rate: 103.52, 30 Jun 2021 spot rate: 110.54 1. Includes Investing, financing and FX related movements

## Unchanged FY2021 financial guidance (12m to 31-Dec-21)

#### Cash R&D expenses

#### ¥4,000 to 5,000m

- Increased investment in HTL'878 selective M<sub>4</sub>R agonist program – valuable opportunity to secure a new major partnership
- Accelerate new and prioritized inhouse programs with strong value creation potential

#### Cash G&A expenses

#### ¥1,800 to 2,300m

- Continued global implementation of Oracle Netsuite Enterprise Resourcing Planning (ERP) system
- Continued build-out of Compliance and Governance capabilities

Investing today to drive growth tomorrow



Guidance (Dec-21)

# Successful international offering and buyback of existing bonds completed after the period ended

Net proceeds of ¥29.8bn from Euro-Yen denominated convertible bonds due 2026



Largest mid-cap convertible bond raise in Asia Pacific region since 2015



Highly successful liability management exercise, with strong 98% investor take-up

Lowered Group's funding cost, extended maturity of debt and potentially reduced dilution upon conversion

#### Use of proceeds:

- Approximately ¥18.9bn to be allocated towards the **repurchase of existing convertible bonds** – **completed**
- New ¥10bn net proceeds to be added to existing ¥20.9bn capital and allocated to strategic growth initiatives (acquisitions and/or investments)
- Approximately ¥0.9bn to be allocated towards R&D of new pipeline programs and working capital

We continue to evaluate strategic growth ideas and are well capitalized to execute when a potential opportunity presents itself





## Excellent progress expanding our drug discovery business

Summary Operational Highlights for the 6 months ended 30 June 2021



New strategic technology collaborations with PharmEnable and InveniAI\* for AI-driven drug discovery, and Metrion Biosciences to explore SBDD approaches for ion channels



**Excellent progress across partnered programs** including MC4 antagonist (partnered with Pfizer) and CGRP antagonist (partnered with Biohaven) both entered Phase 1 clinical trials, and StaR<sup>®</sup> proteins delivery to Genentech, all triggering development milestone payments



**Spin-off company Orexia Therapeutics merged into Centessa Pharmaceuticals**, a new asset-centric company, which completed its \$380m raise / \$1.7bn market cap. NASDAQ IPO in June 2021




**Potential clinical candidate for SARS-CoV-2 MPro program have now been identified** and suitable for further development as an oral treatment of COVID-19

World-leading platform for identifying and exploiting new druggable targets, and a corporate strategy designed to deliver value creation for all stakeholders



\* Executed in July 2021 (event occurred post period close)


## 10 drug candidates generated from our SBDD platform have been successfully advanced into clinical trials



One of THE most productive drug discovery teams in the world over the past 12 years



## We saw excellent progress across our deep pipeline and added multiple new technology collaborations



\* The in-house pipeline displayed above includes fully funded programs only and excludes back-up programs and similar indication programs for one target. For example – A2a ant, SSTR5 ag, GLP-1 ant, GLP-2 ant, M1 and M4 backup programs (list not exhaustive)

## Next wave of COVID-19 therapies – SARS-CoV-2 protease inhibitors – are starting to show promise

	<b>Pfizer</b>	<b>SHIONOGI</b>	SOSEI HEPTARES
Overview	<b>PF-07321332</b> – small molecule oral antiviral treatment; twice a day dosing at first sign of infection / first awareness of an exposure	<b>S-217622</b> – small molecule oral antiviral treatment; once a day dosing.	SH-879 – small molecule oral antiviral treatment; once or twice daily dosing immediately after a positive test result and for up to 2 weeks after
Phase	Phase 2/3 trial initiated in July 2021 for PF-07321332/ritonavir combo	Japanese Phase 1 trial initiated in July 2021	Potential clinical candidate identified suitable for further development
Key data findings	<ul> <li>Exhibits potent <i>in vitro</i> antiviral activity against SARS-CoV-2</li> <li>Robust preclinical antiviral effect and good preclinical safety profile,</li> <li>Good tolerability, no safety findings up to 500mg dose 2x daily with ritonavir/10 days in healthy volunteers</li> <li>Requirement for ritonavir combination boost exposure</li> </ul>	<ul> <li>Animal studies showed ability to decrease the viral load quickly and significantly</li> <li>No safety concerns reported so far</li> </ul>	<ul> <li>Comparable antiviral activity to Pfizer's PF-07321332 against SARS-CoV-2 in cell based assays</li> <li>Low <i>in vitro</i> clearance, superior <i>in</i> <i>vivo</i> clearance and high plasma exposure from oral dosing</li> <li>Does not likely require co-dosing with ritonavir for PK boosting in human clinical trials, unlike Pfizer's PF-07321332</li> </ul>



## Our M<sup>Pro</sup> inhibitor SH-879 represents an excellent opportunity for further development as an oral drug for the treatment of COVID-19

#### **TARGET PRODUCT PROFILE**

Once or twice daily oral agent for treatment of SARS-CoV-2 viral infection dosed immediately after a positive test result and for up to 2 weeks thereafter, with potential for broader application for intervention of associated human coronavirus infections


#### **PROGRAM STAGE**


Excellent progress has been made in >1 chemical series of inhibitors since project initiation Apr-20


Potential clinical candidates have now been identified, suitable for further development

Promising PK results from SH-879, our most advanced asset (see adjacent charts for cell-based antiviral assay data)

\* Regardless of pandemic/endemic status. List of LDCs as defined by the United Nations.







#### NEXT STEPS

Proactively seeking funding via charitable organizations and trusts / other philanthropic sources of funding, to rapidly progress our molecules

Program is available for global partnering to accelerate progress to human clinical trials Significant inbound interest received and under assessment

Program remains a core ESG project – We will not profit/receive economics from sales to Least Developed Countries\*. For all other countries, we will reinvest a portion of any profits received towards our Group's ESG initiatives



## Organic growth plan driving our world-leading GPCR drug discovery



Continuing to build a broad pipeline of high-value creating programs, partnerships and co-investments



## Strategic growth plan driving corporate value expansion



Seeking to add new revenues, access new technologies, and expand and future-proof our capabilities



Muscarinic Agonist Programs – A neuroscience pipeline with a multi-blockbuster profile Dr. Tim Tasker, CMO

3

## Recapping the status and progress of our Muscarinic programs



Patented StaR<sup>®</sup> technology enabled SBDD approach to identify novel highly selective muscarinic  $M_4R$ ,  $M_1R$  and dual  $M_1R/M_4R$  orthosteric agonists



Muscarinic M<sub>4</sub>R and M<sub>1</sub>R represent **clinically validate**d targets for the treatment of psychosis and cognition, precedented by non-selective muscarinic agonists (e.g. xanomeline) in short term clinical studies (5 weeks) in schizophrenia ("SZ") and mild-moderate Alzheimer's disease ("AD") (6 months)



**Multi-blockbuster commercial opportunity** for orally dosed novel mechanisms targeting control of positive symptoms and with an improved safety profile over current Standard of Care. Further improvement in efficacy an upside



**Increased investment in M<sub>4</sub>R agonist program** this year (following reversion in early 2021), with **program nearing Phase 2 readiness for SZ** with a back-up compound which is Phase 1 ready



New  $M_1R$  agonist and a dual  $M_1R/M_4R$  agonist IND ready in 2022, utilizing Proof of Mechanism data in AD from pathfinder compound to accelerate early development

Lead M<sub>4</sub>R orthosteric agonist (HTL'878) Ph 2 ready in the near term, and a first-in-class M<sub>1</sub>R orthosteric agonist compound IND ready in 2022 whilst maintaining a broad muscarinic portfolio



Our Muscarinic programs represent a ready-made neuroscience pipeline with multiple blockbuster opportunities

Program	Compound	Indication	Discovery	Preclinical	Phase 1	Phase 2	Next Milestone 12-18 months
M₄R	HTL'878	Schizophrenia					Phase 2 ready
ortho agonist	Not disclosed	Schizophrenia					Completion of Phase 1 SAD
M <sub>1</sub> R/M <sub>4</sub> R dual ortho agonist	Not disclosed	Schizophrenia & Alzheimer's cognition & psychosis					IND ready
M <sub>1</sub> R	HTL'318	Alzheimer's Dementia Lewy Bodies					Regulatory consultation
ortho agonist pathfinders	HTL'936	Alzheimer's Dementia Lewy Bodies					Clinical PK
M₁R ortho agonist	Not disclosed	Alzheimer's Dementia Lewy Bodies					IND ready

Negotiations progressing well with multiple potential global development/co-development partners. Current intention remains to partner all programs in order to aggressively accelerate their development

Key: Full box = completed phase. Striped box = next milestone



## 4<sup>th</sup>-gen candidates aim to be effective treatments for SZ with fewer side effects



						Efficacy		Saf	ety
					Positive symptoms	Negative symptom	Cognitive impairment	Extrapyramidal symptoms <sup>**</sup>	Weight gain
	MoA	Typical medicine	Peak sales example	Generation	Number of patients 20M*	Number of patients 11.5M <sup>*</sup>	Number of patients 16M*	-	-
Typical antipsychotic	D2 Ant	Haldol	(Historic data unavailable)	1 <sup>st</sup>	+++	-	-	++++	+
Atypical antipsychotics	D2 Ant + 5-HT Regulator	Zyprexa Risperdal Latuda	Zyprexa \$5,000M+ (2010)	2 <sup>nd</sup>	+++	+	+	++	++++
	D2 partial Ag + 5-HT Regulator	Abilify REXULTI Vraylar	Abilify \$6,100M+ (2013)	3 <sup>rd</sup>	+++	+	+	+	+
	M <sub>4</sub> R Agonist <sup>***</sup>	KarXT CVL-231 <b>HTL'878</b>	-	4 <sup>th</sup>	+++	++	++	-	-

Following reversion in early 2021, HTL'878 was rapidly positioned for success in SZ

\*As 1 patient can have several symptoms, number of patients in 3 symptoms is overlapping

\*\*Drug-induced movement disorders including involuntary or uncontrollable movements. tremors. muscle contractions. It is said to be related with D2 receptor occupancy balance.

\*\*\*Expected efficacy and expected safety derived from ongoing clinical trials of KarXT and CVL-231.

22 Source : P T. 2014 Sep; 39(9): 638–645, J Clin Psychiatry. 2010;71(3):280–286, Schizophr Bull. 2010 Jan; 36(1): 36–42 and EvaluatePharma



Modulation of the muscarinic M<sub>4</sub>R now an increasingly de-risked and validated target for treating multiple types of SZ



	<b>KARUNA</b> THERAPEUTICS	Cerevel	SOSEI HEPTARES
Lead Program	KarXT	CVL-231	HTL'878
MoA	M <sub>1</sub> <b>R</b> /M <sub>4</sub> R Agonist, M <sub>2</sub> <b>R</b> /M <sub>3</sub> R Antagonist	$M_4 R PAM^1$	M <sub>4</sub> R Direct Agonist
Current Phase (most advanced)	Phase 3	Phase 1b	Phase 2 ready (near term)
Target	<ul> <li>✓ SZ (Psychosis) - Ph3</li> <li>✓ SZ (Negative and cognitive symptom) - Ph1</li> <li>✓ Dementia-related Psychosis - Ph1</li> </ul>	<ul> <li>✓ SZ (negative, positive and general psychopathology) – Ph1b</li> </ul>	-
Impact of	Ph. 2 met primary endpoint (Nov 18, 2019)	Ph. 1b Positive Topline (June 29, 2021)	
recent Clinical data <sup>*</sup>	\$17.68 → \$85.10 <b>(\$1.7Bn+ Market cap increase)</b>	$$12.57 \rightarrow $23.20$ (\$1.6Bn+ Market cap increase)	-

Recent positive trial results with KarXT and CVL-231 are fueling broad investor and pharma industry interest in the muscarinic class - including our highly selective M<sub>4</sub>R direct agonist approach for SZ

\*Share price change is 5 business days after announcement. <sup>1</sup> PAM = Positive Allosteric Modulator Source: Company Announcements, FactSet



# HTL'878 is differentiated and is the only highly selective HTL'878 orthosteric agonist of the muscarinic M4 receptor in development

Direct agonism of M<sub>4</sub>R is a clinically validated target for psychoses

- Direct agonism of the muscarinic M<sub>4</sub> mechanism is a clinically validated target for the treatment of psychoses (Xanomeline, KarXT), underpinned by strong non-clinical science from around the world
- HTL'878 has been shown to act via selective direct agonism of the M<sub>4</sub>R in non-clinical species and also in humans

HTL'878 is an orthosteric partial direct M<sub>4</sub>R agonist with a potentially improved sideeffect profile

- HTL'878 is an orthosteric partial direct M<sub>4</sub>R agonist with a potentially improved side effect profile in comparison with the front-runner (KarXT) and likely CVL-231
  - HTL'878 has much better selectivity and a potentially improved side-effect profile than KarXT
- CVL-231 is a Positive Allosteric Modulator (PAM) which therefore requires ACh tone in the CNS making it difficult to achieve a margin over CV side effects
- Efficacy of an orthosteric agonist does not depend on cholinergic tone, unlike a PAM we expect also stronger efficacy in Dementia Related Psychosis than a PAM which is unlikely to be effective


Of the fourth-generation treatments in development, HTL'878 stands out as a potentially superior approach



## **Q&A** Shinichi Tamura, Chairman and CEO


## Thank you for your attention

Summary Financial and Operational Highlights for the 6 months ended 30 June 2021



World-leading platform for identifying and exploiting new druggable targets, and a corporate strategy designed to deliver value creation for all stakeholders





## Appendix

### **Progression of Partnered Pipeline**

FY2020 stage FY2021-Now progress

Compound	Target / Mechanism of Action	Modality	Indication	Partner	Disc.	PCC	Ph1	Ph2	Ph3	Арр	Mkt
Traditional Out-licensing	; Collaborations										
Seebri <sup>®</sup> Breezhaler <sup>®</sup>	LAMA	SME	COPD	🔥 novartis							_
Ultibro <sup>®</sup> Breezhaler <sup>®</sup>	LAMA+LABA	SME	COPD	🔥 novartis				_		_	
Enerzair <sup>®</sup> Breezhaler®	LAMA+LABA+ICS	SME	Asthma	🔥 novartis		_				_	
ORAVI®	Antifungal agent miconazole	SME	Oropharyngeal candidiasis	FUJIFILM		_				_	
Imaradenant	Adenosine A2a ant. combo	SME	mCRPC	AstraZeneca							
PF-07081532	GLP-1 agonist	SME	T2DM / Obesity	<b>P</b> fizer							
PF-07054894	CCR6 antagonist	SME	Inflammatory bowel disease	<b>P</b> fizer							
PF-07258669	MC4 antagonist	SME	Anorexia	<b>e</b> Pfizer	_						
BHV3100	CGRP antagonist	SME	Neurology diseases	biohaven							
Not disclosed	GPR35 agonist	SME	Inflammatory bowel disease	gsk							
Not disclosed	Multi target	SME	Multiple indications	<b>Pfizer</b>							
Not disclosed	Multi target	SME/LME	Multiple indications	Genentech							
Not disclosed	Multi target	SME/LME	Gastrointestinal and other	Takeda							
Not disclosed	Single target	SME	Inflammatory diseases	abbvie							
Co-development / Profit	-share Collaborations										
KY1051	CXCR4 mAb	mAb	Immuno-oncology	sanofi 🦻 kymab							
Not disclosed	PAR-2	Peptide	Inflammatory diseases	Contraction Contraction							
Not disclosed	Targeted Protein Degradation	SME	Gastrointestinal disorders	Captor Therapeutics®							
Not disclosed	AI-Augmented Drug Discovery	SME	Neurology diseases	D PHARMENABLE							
Not disclosed	Ion Channel Drug Discovery	SME	Neurology diseases	metrion							
Not disclosed	Multi target AI-powered	SME	Immune diseases	Inveni 🔕							
Co-owned investments											
TMP301	mGlu5 NAM	SME	Substance use disorders	Tempero. Bio							
Not disclosed	OX1/OX2 agonist(oral and intranasal)	SME	Narcolepsy								



Note: SME = small molecule. LME = large molecule. Seebri<sup>®</sup>, Ultibro<sup>®</sup>, Enerzair<sup>®</sup> and Breezhaler<sup>®</sup> are registered trademarks of Novartis AG.

### **Progression of In-house Pipeline**

FY2020 stage FY2021-Now progress

Compound	Target / Mechanism of Action	Modality	Indication	Originator	Dis	PCC	Ph1	Ph2	Ph3	Арр	Mkt.
In-house Programs (Not	yet partnered)										
HTL'878	Muscarinic M4 agonist	S <mark>ME</mark>	Neurology diseases	SOSEI HEPTARES							
HTL'318 <sup>1</sup>	Muscarinic M1 agonist	S <mark>ME</mark>	Neurology diseases	SOSEI HEPTARES							
HTL'936	Muscarinic M1 agonist	S <mark>ME</mark>	Neurology diseases	SOSEI HEPTARES	_						
Not disclosed	Muscarinic M1 agonist (B/U)	SME	Neurology diseases	SOSEI HEPTARES							
Not disclosed	Muscarinic M4 agonist (B/U)	SME	Neurology diseases	SOSEI HEPTARES							
Not disclosed	Muscarinic M1/M4 agonist	SME	Neurology diseases	SOSEI HEPTARES							
Not disclosed	H4 antagonist	SME	Atopic Dermatitis	SOSEI HEPTARES							
Not disclosed	EP4 antagonist	SME	Immuno-oncology	SOSEI HEPTARES							
Not disclosed	GPR52 agonist	SME	Neurology diseases	SOSEI HEPTARES	_						
Not disclosed	PAR-2 mAb	mAb	Atopic Dermatitis								
SH-879	SARS CoV-2 Mpro	SME	Coronaviruses		_						
Not disclosed	EP4 agonist	SME	Inflammatory bowel disease		_						
Multiple programs	Not disclosed	SME/LME	Neurology diseases		_						
Multiple programs	Not disclosed	SME/LME	GI and Inflammatory diseases		_						
Multiple programs	Not disclosed	SME/LME	Immunology diseases	SOSEI HEPTARES	_						
In-house Programs (No lo	onger internally funded. Targetir	ng academic / indus	trial partnership)								
HTL'310	SSTR5 agonist	Peptide	Hypoglycaemic disorders								
HTL'097	GLP-1 antagonist	Peptide	Hypoglycaemic disorders								
HTL'023	Dual GLP-2/GLP-1 agonist	Peptide	Intestinal failure / NASH								
Not disclosed	Apelin agonist	Peptide	Pulmonary Arterial Hypertension								
HTL'641	Dual orexin antagonist	SME	Insomnia and sleep disorders		_						

SOSEI HEPTARES

Note: SME = small molecule. LME = large molecule. <sup>1</sup> Voluntarily suspended

## M<sub>4</sub>R PAM less likely to be successful in DRP than an M<sub>4</sub>R Agonist

- CVL-231 probability of success in dementia remain uncertain as cholinergic system significantly altered

- Xanomeline did show efficacy in psychotic symptoms in Alzheimer's Disease, providing validation for an agonist

- Is there sufficient ACh tone in AD or will the patient population be too heterogeneous for a PAM to work?
- DRP is most prominent in moderate to severe AD where ACh deficiency greatest a PAM is unlikely to work in this setting?
- Merck M<sub>1</sub>R PAM had positive data in Phase 1 in volunteers but failed in AD

		Cerevel	SOSEI HEPTARES
Lead Program	KarXT Fixed dose combination of xanomeline + trospium	CVL-231	HTĽ 878
Pharmacological approach to tolerability	Mixed muscarinic agonist and peripheral antagonist (combination product)	Pure M <sub>4</sub> R Positive Allosteric Modulator	Pure M <sub>4</sub> R orthosteric partial agonist
Rationale	Peripheral antagonist <u>masks</u> some of the poorly tolerated muscarinic side effects of mixed agonists. <u>Brings</u> kinetics and tolerability probs.	<b><u>Avoids</u></b> non- $M_4R$ muscarinic side effects. <u><i>Cannot</i></u> reduce peripheral $M_4R$ cardiovascular effects.	<u><b>Avoids</b></u> non- $M_4R$ muscarinic side effects. <u><i>Might</i></u> reduce peripheral $M_4R$ cardiovascular effects.
Status	Lilly data on Xanomeline showed positive POC in a small AD trial Strong, positive efficacy data Significant, GI Adverse Events &	PAM cannot produce M <sub>4</sub> R system stimulation in this patient group due to the lack of cholinergic tone? Will CV effects be tolerable in a frail elderly population?	Ready for phase 2; Well-tolerated dose and regimen for Phase 2 established by thorough Phase 1



Source: Bymaster et al, DRUG DEVELOPMENT RESEARCH 40:158–170 (1997)

### Sosei Heptares M<sub>4</sub>R Receptor Orthosteric Partial Agonist HTL'878


Intracellular

"coupling"

drives

effects

- Potentially superior clinical profile compared to a PAM such as CVL-231
- Superior selectivity profile to KarXT



- PAM unlikely effective in DRP
- Central and peripheral receptors affected identically, will also drive effects in the periphery
- Peripheral AEs are unavoidable

HTL'878 binds to a partial agonist receptor conformation acting as a replacement for Ach ' 878 distributes well to brain (Ph I data)

HTL'878 is a highly selective partial agonist :

- Specific activation of the M<sub>4</sub>R without the need for Ach – More effective in DRP
- Better control of ACh release to modulate DA
- No unwanted effects from M<sub>1</sub>, M<sub>2</sub>, M<sub>3</sub> or M<sub>5</sub> receptors due to high selectivity
- Partial agonist drives well coupled central effects with reduced effects on peripheral less-well coupled systems
- Separation of central and peripheral effects focussing M<sub>4</sub>R effects in the brain



Potential Market of M<sub>1</sub> Ag Adding on to Donepezil (standard therapy, peak sales was \$3,9BN+), potential to be best in class

		Alz	חוס		
		Mild	Moderate	Severe	DLB
		Number of patients (2030 forecast) $18.5 M$	Number of patients (2030 forecast) $11.5 M$	Number of patients (2030 forecast) 5.2M	Number of patients (2030 forecast) $6.5 M$
Symptomatic	M₁R Agonist (Adding on to donepezil)	Target of HTL'3	818 (Ph1)		Ph2 of HTL'318 planned in Japan and suspended
drug	Ex. Aricept(Donepezil) Peak sales : c. \$3,900M+ (2009)			Expanded indication	Expanded indication (Japan only)
Disease-modifying drug	Ex. Aduhelm (Aducanumab)				



Source : EvaluatePharma

## Locations

### SOSEI HEPTARES

PMO Hanzomon 11F 2-1 Kojimachi, Chiyoda-ku Tokyo 102-0083 Japan Steinmetz Building Granta Park, Cambridge CB21 6DG United Kingdom

North West House 119 Marylebone Road London NW1 5PU United Kingdom